HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

DSR-29133

a toll-like receptor 7 (TLR7) agonist with immunomodulating and antineoplastic activites; structure in first source

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - Adenine: 2120
        DSR-29133: 1

Experts

1.	Adlard, Amy L: 1 article (03/2016)
2.	Cheadle, Eleanor J: 1 article (03/2016)
3.	Dovedi, Simon J: 1 article (03/2016)
4.	Eguchi, Ken: 1 article (03/2016)
5.	Hirose, Yuko: 1 article (03/2016)
6.	Honeychurch, Jamie: 1 article (03/2016)
7.	Hughes, Gareth: 1 article (03/2016)
8.	Illidge, Timothy M: 1 article (03/2016)
9.	Jewsbury, Philip J: 1 article (03/2016)
10.	Koga-Yamakawa, Erina: 1 article (03/2016)

Related Diseases

1.	Colorectal Neoplasms (Colorectal Cancer) 03/29/2016 - "Administration of DSR-29133 leads to the induction of IFNα/γ, IP-10, TNFα, IL-1Ra and IL-12p70, and to a reduction in tumor burden in syngeneic models of renal cancer (Renca), metastatic osteosarcoma (LM8) and colorectal cancer (CT26). "
2.	Osteosarcoma (Osteogenic Sarcoma) 03/29/2016 - "Administration of DSR-29133 leads to the induction of IFNα/γ, IP-10, TNFα, IL-1Ra and IL-12p70, and to a reduction in tumor burden in syngeneic models of renal cancer (Renca), metastatic osteosarcoma (LM8) and colorectal cancer (CT26). "
3.	Neoplasms (Cancer) 03/29/2016 - "These results demonstrate that DSR-29133 is a potent selective TLR7 agonist that when administered intravenously can induce anti-tumor immune responses that can be further enhanced through combination with low-dose fractionated RT. " 03/29/2016 - "Moreover, long-term surviving mice originally treated with DSR-29133 and RT were protected by a tumor-specific memory immune response which could prevent tumor growth upon rechallenge. " 03/29/2016 - "Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy." 03/29/2016 - "Administration of DSR-29133 leads to the induction of IFNα/γ, IP-10, TNFα, IL-1Ra and IL-12p70, and to a reduction in tumor burden in syngeneic models of renal cancer (Renca), metastatic osteosarcoma (LM8) and colorectal cancer (CT26). "
4.	Kidney Neoplasms (Kidney Cancer) 03/29/2016 - "Administration of DSR-29133 leads to the induction of IFNα/γ, IP-10, TNFα, IL-1Ra and IL-12p70, and to a reduction in tumor burden in syngeneic models of renal cancer (Renca), metastatic osteosarcoma (LM8) and colorectal cancer (CT26). "

Related Drugs and Biologics

1.	Interleukin 1 Receptor Antagonist Protein (Anakinra)
2.	Toll-Like Receptor 7

Related Therapies and Procedures

1.	Intravenous Administration
2.	Radiotherapy